New foam aims to soothe immunotherapy skin side effects
NCT ID NCT07639840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a medicated foam called roflumilast on skin rashes caused by checkpoint inhibitor cancer drugs. Twenty adults with mild to severe rash will apply the foam daily for 16 weeks. The goal is to see if it safely reduces rash severity and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- roflumilast foam 0.3%
- What this could lead to
- If it works, this could offer a new topical treatment to ease skin rashes from cancer immunotherapy, improving comfort without stopping cancer treatment.
- What could go wrong
- This is a small, early-phase trial with only 20 people, so results may not apply to everyone. The rash may not improve, or side effects could occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.